• Mersana Therapeutics Inc MRSN.OQ reported a quarterly adjusted loss of $4.87​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-5.00. The mean expectation of eight analysts for the quarter was for a loss of $3.93 per share. Wall Street expected results to range from $-5.25 to $-2.00 per share.

• Revenue rose 33.3% to $3.06 million from a year ago; analysts expected $6.36 million.

• Mersana Therapeutics Inc's reported EPS for the quarter was a loss of $4.87​.

• The company reported a quarterly loss of $24.3 million.

• Mersana Therapeutics Inc shares had fallen by 18.0% this quarter and lost 83.0% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 20.6% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Mersana Therapeutics Inc is $137.50, about 95.6% above its last closing price of $6.07

This summary was machine generated from LSEG data August 13 at 01:32 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)